NYXOAH SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.2 EUR | +1.77% |
|
-3.16% | +115.96% |
| Apr. 12 | Nyxoah Names New Chief Medical Officer | MT |
| Apr. 12 | Nyxoah S.A. Appoints Maurits Boon as Chief Medical Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
9.2
EUR
Average target price
15.5
EUR
Spread / Average Target
+68.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +115.96% | 276M | |
| +2.64% | 207B | |
| +1.80% | 175B | |
| +8.59% | 132B | |
| +16.47% | 99.1B | |
| -3.42% | 60.89B | |
| +12.71% | 52.04B | |
| -6.61% | 45.48B | |
| -4.53% | 38.81B | |
| +9.27% | 38.77B |
- Stock Market
- Equities
- NYXH Stock
- News Nyxoah SA
- Nyxoah : Sleep Device Meets Primary Endpoint of Clinical Study
